JPRN-jRCT1040210119已完成未知
Genetic Analysis of Gastrointestinal Neuroendocrine Tumors (GI-NET) Identified With Different Risks of Prognosis Multicenter Retrospective Cohort - GARNET
Mizuno Nobumasa0 个研究点目标入组 41 人开始时间: 2021年12月26日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 41
研究概览
简要总结
Rectal NETs with unfavorable outcomes (cohorts B and C) had unique genomic and epigenetic alterations, which might be used as a prognostic marker for risk stratification of rectal NETs.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Provision of written informed consent prior to any study related procedures.
- •2.Diagnosed to be suffering from advanced rectal NET (World Health Organization Grade 1 or 2, up to 20% Ki-67).
- •3.Male or female, aged 18 or older.
- •4.An archival tissue sample (at the time of initial diagnosis before intervention) of the primary tumor by endoscopic biopsy must be available for molecular testing. If the sample volume is insufficient, surgical specimens or specimens from metastases must be available.
- •5.Cohort A
- •T2N1M0 or higher at the first diagnosis (Stage III).
- •Recurrence-free survival of 5 years or more from initial surgical treatment (at the time of enrollment).
- •No distant metastases (including regional lymph node metastases).
- •6.Cohort B
- •Distant metastases (excluding regional lymph node metastases).
- •Survival period of 3 years or more after distant metastasis diagnosis (at the time of data cutoff).
- •7.Cohort C
- •Distant metastases (excluding regional lymph node metastases).
- •Survival period of less than 3 years from distant metastasis diagnosis (at the time of data cutoff).
- •Patients who died due to reason current tumor.
排除标准
- •1.Patients diagnosed with NEC and MiNEN.
- •2.Neuroendocrine tumors that do not originate in the rectum.
- •3.Patients with NET G3 (Ki-67 > 20).
- •4.Patients who received peptide receptor radionuclide therapy (PRRT).
- •5.Patients who died due to reasons other than current tumor reason (e.g. side effects of drugs, suicide).
- •6.Tissue sample that collected after drug intervention for NET.
- •7.Cohort A
- •Patients who have only undergone endoscopic resection (endoscopic sub-mucosal dissection (ESD), endoscopic mucosal resection (EMR) etc.)
- •Patients who have record of recurrence or death.
研究者
相似试验
已完成
不适用
The Endocrine Secretome After Gastric Bypass SurgeryObesity, MorbidType2 DiabetesNCT03093298Filip Krag Knop28
已完成
不适用
Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine CarcinomaColorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5NCT05714722Zhejiang University60
招募中
不适用
Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsNeuroendocrine Neoplasm of Gastrointestinal TractNeuroendocrine Neoplasm of LungThymic Neuroendocrine NeoplasmNeuroendocrine Tumor of PancreasGastrointestinal Stromal TumorsMedullary Thyroid CancerPheochromocytomaNeuroendocrine NeoplasmMultiple Endocrine Neoplasia Type 4Carney ComplexCarney Stratakis DyadCarney TriadDICER1 SyndromeLi-Fraumeni SyndromeLynch SyndromeVon Hippel-Lindau DiseaseFamilial Isolated Pituitary AdenomaX-Linked AcrogigantismMultiple Endocrine Neoplasia Type 2Cowden SyndromeNeurofibromatosis 1Tuberous SclerosisPituitary TumorMultiple Endocrine Neoplasia Type 1Primary HyperparathyroidismParagangliomaNCT06523582Universidad Nacional Autonoma de Mexico750
已完成
不适用
Gastrointestinal hormones and genes associated to type 2 diabetes remission in non-morbid obesity after bariatric surgeryType 2 diabetesNutritional, Metabolic, EndocrineNon-insulin-dependent diabetes mellitusISRCTN57114193Fundación Mutua Madrileña (Spain)60
招募中
不适用
Genetic analysis of multiple endocrine neoplasia type 1multiple endocrine neoplasia type 1JPRN-UMIN000037109Kagawa University Hospital10